CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines

被引:0
|
作者
Lori J. Pobst
Matthew M. Ames
机构
[1] Mayo Clinic College of Medicine,Department of Molecular Pharmacology and Experimental Therapeutics
来源
关键词
Aminoflavone; Cytochrome P450; H2AX; Alkaline elution; MCF7; Topoisomerase;
D O I
暂无
中图分类号
学科分类号
摘要
Purpose: Aminoflavone (5-amino-2,3-fluorophenyl)-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one; AF; NSC 686288) is a novel anticancer agent with a unique pattern of growth inhibitory activity in the National Cancer Institute (NCI) 60 tumor cell line screen. Phase I clinical trials with AF will begin soon. We previously demonstrated extensive metabolism of AF by cytochrome P450 (CYP) 1A1 and CYP1A2, metabolic activation, formation of irreversible protein and DNA adducts and p53 stabilization in sensitive, but not resistant, human tumor cell lines treated with AF [9]. The present studies focus on the effects of AF on cellular DNA and cellular responses to DNA damage. Methods: Phosphorylation of H2AX in MCF7 cells treated with AF was determined with immunofluorescence. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium) assays were used to determine the effect of cotreatment with caffeine or wortmannin, inhibitors of ataxia-telangiectasia-mutated protein (ATM) and ATR (ATM- and rad3-related protein), on the AF IC50 values for MCF7 cells. DNA damage in MCF7 cells treated with AF was determined by alkaline elution. DNA-topoisomerase complex stabilization was ascertained by the ICE (in vitro complex of enzyme) assay. Results: Treatment of sensitive cells with AF resulted in phosphorylation of H2AX, a histone 2A variant that is phosphorylated in response to DNA damage. AF IC50 values for MCF7 cells were lowered by cotreatment with caffeine or wortmannin, further implicating DNA damage in AF cytotoxicity. There was no evidence of DNA–DNA cross-linking in sensitive cells, but protein-associated single-strand breaks were observed after AF treatment. Although this pattern of DNA damage is commonly associated with topoisomerase poisons, there was no evidence for AF-induced stabilization of either topoisomerase I- or II-DNA complexes. Conclusions: These studies further implicate DNA damage in the cytotoxicity of AF and identify biochemical features of that damage including formation of protein-associated single-strand breaks not involving topoisomerase I or II.
引用
收藏
页码:569 / 576
页数:7
相关论文
共 50 条
  • [21] Characterization of human CYP1A1/1A2 induction by DNA microarray and α-naphthoflavone
    Ishida, S
    Jinno, H
    Tanaka-Kagawa, T
    Ando, M
    Ohno, Y
    Ozawa, S
    Sawada, J
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (01) : 172 - 177
  • [22] Disruption of the Gene for CYP1A2, which Is Expressed Primarily in Liver, Leads to Differential Regulation of Hepatic and Pulmonary Mouse CYP1A1 Expression and Augmented Human CYP1A1 Transcriptional Activation in Response to 3-Methylcholanthrene In Vivo
    Jiang, Weiwu
    Wang, Lihua
    Kondraganti, Sudha R.
    Fazili, Inayat S.
    Couroucli, Xanthi I.
    Felix, Edward A.
    Moorthy, Bhagavatula
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (02): : 369 - 379
  • [23] A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes
    Ueda, Rika
    Iketaki, Hiromi
    Nagata, Kiyoshi
    Kimura, Shioko
    Gonzalez, Frank J.
    Kusano, Kazutomi
    Yoshimura, Tsutomu
    Yamazoe, Yasushi
    MOLECULAR PHARMACOLOGY, 2006, 69 (06) : 1924 - 1930
  • [24] Expression of the human CYP1A1 gene in mice
    Beaton, D
    Nguyen, N
    Galijatovic, A
    Bonzo, J
    Tukey, RH
    FASEB JOURNAL, 2004, 18 (08): : C86 - C86
  • [25] Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells
    Spink, DC
    Spink, BC
    Cao, JQ
    DePasquale, JA
    Pentecost, BT
    Fasco, MJ
    Li, Y
    Sutter, TR
    CARCINOGENESIS, 1998, 19 (02) : 291 - 298
  • [26] In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1
    Rochat, Bertrand
    Zoete, Vincent
    Grosdidier, Aurelien
    von Gruenigen, Sandrine
    Marull, Marc
    Michielin, Olivier
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2008, 29 (02) : 103 - 118
  • [27] Silencing of CYP1A1 expression in rabbits by DNA methylation
    Takahashi, Y
    Suzuki, C
    Kamataki, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (02) : 383 - 386
  • [28] CYP1A1 and CYP1A2 expression: Comparing 'humanized' mouse lines and wild-type mice; comparing human and mouse hepatoma-derived cell lines
    Uno, Shigeyuki
    Endo, Kaori
    Ishida, Yuji
    Tateno, Chise
    Makishima, Makoto
    Yoshizato, Katsutoshi
    Nebert, Daniel W.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 237 (01) : 119 - 126
  • [29] CYP1A2 is expressed along with CYP1A1 in the human lung
    Wei, C
    Cacavale, RJ
    Kehoe, JJ
    Thomas, PE
    Iba, MM
    CANCER LETTERS, 2001, 164 (01) : 25 - 32
  • [30] CYP1A1 but not CYP1A2 proteins are expressed in human lymphocytes
    Spatzenegger, M
    Horsmans, Y
    Verbeeck, RK
    PHARMACOLOGY & TOXICOLOGY, 2000, 86 (05): : 242 - 244